Barclays analyst Emily Field lowered the firm’s price target on Genmab to DKK 2,500 from DKK 2,800 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Epcoritamab Poised to Transform Lymphoma Treatment
- Genmab gets CHMP opinion recommending marketing authorization of epcoritamab
- Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
- Genmab Completes Share Buy-back Program Early
- Completion of Share Buy-back Program
Questions or Comments about the article? Write to editor@tipranks.com